Coronary Artery Disease Clinical Trial
— EXecutiveOfficial title:
EXecutive Randomized Controlled Trial (RCT): XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease.
The purpose of this two part study is the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific setting of patients with Multi-Vessel Coronary Artery Disease (MVD).
Status | Completed |
Enrollment | 200 |
Est. completion date | June 2011 |
Est. primary completion date | March 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Patient must be at least 18 years of age 2. Patient is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the XIENCE V® EECSS and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure, as approved by the appropriate Medical Ethics Committee of the respective clinical site 3. Patient has been diagnosed a MVD, as documented by coronary angiography, i.e. presenting a severe stenosis (>50%) amenable to PCI in at least 2 major epicardial vessels or their principal bifurcation branches (diagonal or obtuse marginal) 4. Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or a reversible change in the electrocardiogram -ECG- consistent with ischemia) 5. Patient must be an acceptable candidate for coronary artery bypass graft (CABG) surgery 6. Patient must agree to undergo all protocol-required follow-up examinations. Angiographic Inclusion Criteria 1. Patients may receive up to 4 planned XIENCE V® EECSS stents, depending on the number of vessels treated and their respective lesion length. When multiple lesions are present in one or more main coronary branches, complete revascularization should be attempted with the implantation of a maximum of 4 planned stents 2. Target lesions must be de novo lesions (no prior stent implant, no prior brachytherapy) 3. Target vessel reference diameter must be between 2.5 mm and 4.0 mm by visual estimate 4. Target lesion < or = 28 mm in length by visual estimation 5. Target lesions must be in a major artery or its principal branches (diagonal or obtuse marginal) with a visually estimated stenosis of > or = 50% 6. Two lesions in a single main coronary artery or its branches do not constitute a MVD situation, therefore this type of patient must not be enrolled Exclusion Criteria: 1. Patient has had a known diagnosis of acute myocardial infarction (AMI) within 72 hours preceding the index procedure (non-procedural/spontaneous MI, CK-MB > or = to 2 times upper limit of normal) and CK and CK-MB have not returned within normal limits at the time of procedure 2. Patient has current unstable arrhythmias 3. Patient has a known left ventricular ejection fraction (LVEF) <30% 4. Patient has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant 5. Patient is receiving or scheduled to receive chemotherapy or radiation therapy within 30 days prior to or after the procedure. 6. Patient is receiving immunosuppression therapy or has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.) 7. Patient is receiving chronic anticoagulation therapy (e.g. coumadin) 8. Patient has a known hypersensitivity or contraindication to aspirin, paclitaxel, either heparin or bivalirudin, clopidogrel or ticlopidine, everolimus, cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be adequately pre-medicated 9. Elective surgery is planned within the first 9 months (+/- 14 days) after the procedure that will require discontinuing either aspirin or clopidogrel 10. Patient has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3, a WBC of <3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis) 11. Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5 mg/dl, patient on dialysis) 12. Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions 13. Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months 14. Patient has had a significant GI or urinary bleed within the past six months 15. Patient has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the data interpretation or is associated with a limited life expectancy (i.e. less than one year) 16. Patient is already participating in another investigational use device or drug study or has completed the follow-up phase of another study within the last 30 days. Angiographic Exclusion Criteria 1. Target lesion meets any of the following criteria: - Left main location - Located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft (defined as vessel irregularity per angiogram and >20% stenosed lesion by visual estimation) - Heavy calcification 2. The patient may need more than 4 planned stents. Bailout stents are allowed but must be of the same type as randomization stent. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Italy | A.O. San Giovanni di Dio | Agrigento | |
Italy | Ospedale Maggiore Bologna | Bologna | |
Italy | Policlinico S. Orsola - Malpighi | Bologna | |
Italy | A.O. Cannizzaro | Catania | |
Italy | A.O. Universitaria Vittorio Emanuele - Ferrarotto - S. Bambino | Catania | |
Italy | A.O. Università Mater Domini c/o Campus Università Magna Grecia | Catanzaro | |
Italy | A.O. Universitaria OO.RR Foggia | Foggia | |
Italy | E.O. Ospedali Galliera | Genova | |
Italy | A.O. Carlo Poma | Mantova | |
Italy | Centro Cardiologico Monzino | Milano | |
Italy | Ospedale Loreto Mare | Napoli | |
Italy | A. O. Sant'Andrea | Roma | |
Italy | Ospedale Generale Madre Vannini | Roma | |
Italy | Ospedale Sandro Pertini | Roma | |
Italy | A.S.O. Molinette San Giovanni Battista di Torino | Torino | |
Italy | Ospedale Maria Vittoria | Torino | |
Italy | P.O. San Giovanni Bosco | Torino | |
Italy | San Giovanni Battista - Ospedale Molinette | Torino | |
Italy | A.O. Universitaria - Ospedale Riuniti Umberto I - G.M. Lancisi - G. Salesi | Torrette Di Ancona | |
Italy | Ospedale Civile Maggiore - Università di Verona | Verona | |
Italy | Ospedale Civile | Vicenza | |
Italy | Ospedale Civile di Vigevano | Vigevano | |
Italy | A.O. Della Provincia di Pavia | Voghera | |
Italy | Policlinico San Marco | Zingonia |
Lead Sponsor | Collaborator |
---|---|
Abbott Vascular |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | In-stent Late Loss (LL) | Full Analysis Set (FAS). LL is defined as the difference between the post-procedure (immediately post placement of the stent) minimal lumen diameter (MLD) and the follow-up MLD (at 270 days). In stent is measured within the confines of the stent edges. | at 270 days | Yes |
Secondary | In-stent Binary Restenosis Rate | This measures the percentage of patients who have > 50% diameter stenosis of the assessed vessel, within the stent edges. | at 9 months | Yes |
Secondary | In-segment Binary Restenosis Rate | This measures the percentage of patients who have > 50% diameter stenosis of the assessed vessel, within the stent edges In-segment is measured within the confines of the stent edges plus within 5 mm on either side of the stent. |
at 9 months | Yes |
Secondary | In-segment Late Loss (LL) | LL is defined as the difference between the post-procedure (immediately post placement of the stent) minimal lumen diameter (MLD) and the follow-up MLD (at 270 days). In segment LL is measured within the confines of the stent edges and within 5 mm of those edges. | at 9 months | Yes |
Secondary | Composite Rate of Cardiac Death, Myocardial Infarction (MI, Both Q-wave and Non Q-wave), and Ischemia-driven Target Lesion Revascularization (TLR) . | This measure is a calculation of the percentage of participants who experience any of the components of this composite measure. | at 30 days | Yes |
Secondary | Composite Rate of All Death, MI (Q-wave and Non Q-wave), and Target Vessel Revascularization (TVR). | at 30 days | Yes | |
Secondary | Lesion Success | defined as attainment of < 30% residual in-stent stenosis (by visual assessment) using any percutaneous method. | at the time of PCI | No |
Secondary | Procedural Success | defined as: residual in-stent %DS of < 30% using a percutaneous method, without cardiac death, Q-wave MI, non Q-wave MI, or repeat revasc of the target during hospitalization. | at the time of PCI | Yes |
Secondary | Device Success | defined as achievement of a final residual in-stent diameter stenosis of < 30% (visual assessment) using the assigned device only. | at the time of PCI | Yes |
Secondary | Adjudicated Stent Thrombosis. | at 30 days | Yes | |
Secondary | Adjudicated Stent Thrombosis. | 9 months | Yes | |
Secondary | Revascularizations | (TLR/TVR/any revascularization)both ischemia-driven and not ischemia-driven. | at 30 days | Yes |
Secondary | Revascularizations | (TLR/TVR/any revascularization)both ischemia-driven and not ischemia-driven. | 9 months | Yes |
Secondary | Composite Endpoint of Cardiac Death, MI (Q-wave and Non Q-wave), and Ischemia-driven TLR . | ITT | 9 months | Yes |
Secondary | Composite Endpoint of All Death, MI (Q-wave and Non Q-wave), and TVR. | 9 months | Yes | |
Secondary | In-stent Minimum Lumen Diameter (MLD). | at 9 months. | Yes | |
Secondary | In-segment Minimum Lumen Diameter (MLD). | at 9 months. | Yes | |
Secondary | Proximal Minimum Lumen Diameter (MLD). | Proximal refers to the immediate 5 mm outside of the proximal end of the stent. | at 9 months. | Yes |
Secondary | Distal Minimum Lumen Diameter (MLD). | Distal refers to the immediate 5 mm outside of the distal end of the stent. | at 9 months. | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |